<DOC>
	<DOCNO>NCT02556775</DOCNO>
	<brief_summary>The purpose registry acquire safety data ( include assessment anti-rHuPH20 antibody ) , regard course outcome pregnancy woman ever treat HYQVIA . Development fetus/infant birth first 2 year also follow .</brief_summary>
	<brief_title>Pregnancy Registry Collect Long-Term Safety Data From Women Treated With HyQvia ( Immune Globulin ( Human ) 10 % With rHuPH20 )</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>For expectant mother : Participant become pregnant treatment HYQVIA Participant/Participant 's legally authorized representative willing sign inform consent form ( ICF ) There applicable Exclusion Criteria</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>